Compare Citius Pharmaceuticals Inc (CTXR) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Prudential Financial Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Prudential Financial Inc trades at $115.48 (market cap $39.87B). The key difference: Prudential Financial Inc is far larger — about 2723.4× Citius Pharmaceuticals Inc's market cap, and Prudential Financial Inc pays a 4.88% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PRU | |
|---|---|---|
Market Cap | $14.64M | $39.87B |
Sector | Health | Financials |
52-Week High | $1.82 | $118.72 |
52-Week Low | $0.53 | $92.00 |
Enterprise Value | $10.86M | $66.92B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
PRU trades at $116.17, up 0.69% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 11.96, net income margin of 5.5%, and recent earnings beats in Q3 2025 and Q1 2026. Recent news highlights dividend payments and expansion into India's life insurance market.
The outlook is mixed; solid profitability and low valuation support upside, but analyst consensus is cautious with a $102.50 price target below current levels. Key risks include volatile cash flows and high debt levels. Earnings on August 4, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
